Join our mailing list to receive the latest updates and alerts Flag Subscribe

Fredrikson & Byron acted as legal counsel to Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses, in a licensing agreement that will allow AstraZeneca’s global biologics research and development arm, MedImmune, to develop and, if successful, to commercialize Omnis’s lead oncolytic virus program. Fredrikson’s legal team included Ann M. Ladd and Ryan C. Brauer.

Read the news release.

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.